Veterinary Research Diagnostics
Companion Animal Diagnostics: ELISA Panels for Cats and Dogs
Feline and canine research programs increasingly rely on quantitative immunoassays to characterize inflammation, renal status and humoral immune function without invasive tissue sampling. This guide walks through how biomarker class, sample type and species-specific protein biology should drive ELISA kit selection for cats and dogs, and how individual assays combine into a coherent companion animal diagnostic panel.
Cross-Species ELISA Kit Selection: Sample Type and Biomarker Target
Selecting an ELISA kit for companion animal research is not a matter of picking the closest human analog. Antibody pairs validated for human analytes frequently fail to recognize the feline or canine ortholog of the same protein, because amino acid sequence divergence at the epitope level can be substantial even for well-conserved biomarkers. A kit description should always specify the species it was raised and validated against, and researchers should treat species specificity as a non-negotiable filter before any other selection criterion.
Once species specificity is confirmed, sample type becomes the second filter. Serum, plasma (EDTA, heparin or citrate, depending on the assay), urine and occasionally cerebrospinal fluid or synovial fluid are the common companion animal matrices. Each matrix carries different pre-analytical risks: hemolysis and lipemia are common confounders in serum from clinically ill cats, urine assays require normalization against urinary creatinine to control for variable dilution, and plasma anticoagulant choice can interfere with specific antibody-antigen binding in a minority of assay chemistries. A kit's validated matrix list should match the sample bank available to the study before any catalog comparison proceeds.
| Selection criterion | Why it matters | Practical check |
|---|---|---|
| Species reactivity | Antibody pairs are epitope-specific; cross-reactivity between human, canine and feline targets is not guaranteed | Confirm the kit lists cat or dog explicitly, not \"multi-species\" without species-level validation data |
| Sample matrix | Serum, plasma and urine have different protein concentrations, interferents and stability profiles | Match the kit's validated matrix to the sample type already collected or plannable |
| Biomarker class | Acute phase proteins, renal markers and immunoglobulins answer different physiological questions | Define the research question first, then select the biomarker class, then the kit |
| Dynamic range | Pathological elevations can span orders of magnitude depending on disease severity | Check the standard curve range against expected concentrations in the study population |
| Sample volume | Serial sampling in small companion animals is volume-limited, especially in cats | Confirm minimum sample volume per well and whether replicate testing is feasible |
For teams working across both species, the practical workflow is to first consult the veterinary and animal ELISA kit category to confirm which biomarker families have dedicated feline and canine assays, then narrow further within the companion animal diagnostics subcategory, where panels are organized specifically around cat and dog research use rather than livestock or laboratory rodent applications.
Acute Phase Protein Biology and Its Representation in CRP/AGP ELISA Kits
Acute phase proteins (APPs) are plasma proteins whose concentration changes by a defined percentage within hours to days of an inflammatory stimulus, driven by hepatocyte response to circulating cytokines such as IL-6. In companion animal research, C-reactive protein (CRP) and alpha-1-acid glycoprotein (AGP) are the two most commonly measured positive APPs, but their utility differs meaningfully between cats and dogs.
In dogs, CRP is considered a major acute phase protein: baseline concentrations are low and the magnitude of increase following an inflammatory trigger can be substantial, giving CRP a wide dynamic range and strong signal-to-noise characteristics in canine serum or plasma. This makes canine CRP ELISA data useful for tracking the time course of inflammatory processes or monitoring resolution over repeated sampling points.
Cats behave differently. Feline CRP responses are comparatively modest and more variable, which has led many veterinary researchers to favor AGP as the primary acute phase marker in cats. AGP in cats shows a more consistent and proportionally larger rise during inflammatory states, including chronic conditions where CRP elevation may be subtle or absent. A research design that defaults to CRP for both species without accounting for this difference risks under-detecting inflammatory signal in feline cohorts.
| Marker | Primary species utility | Behavior pattern | Research application |
|---|---|---|---|
| CRP | Dogs (major APP) | Low baseline, large fold-increase with inflammation | Tracking acute inflammatory onset and resolution in canine studies |
| CRP | Cats (minor/variable APP) | Modest, inconsistent elevation | Supplementary marker; interpret alongside AGP |
| AGP | Cats (preferred APP) | Consistent, proportionally larger rise | Primary acute phase marker in feline inflammatory and chronic disease research |
| AGP | Dogs (secondary APP) | Slower kinetics than CRP | Useful for chronic or subacute inflammatory monitoring alongside CRP |
Researchers assembling an inflammation panel should browse the CRP/AGP panel category to compare species-specific kit options side by side, since the underlying assay chemistry and expected concentration ranges differ considerably between canine CRP and feline AGP formats.
Kidney Injury Biomarkers: NGAL and Cystatin C in Veterinary Research Panels
Serum creatinine, the traditional renal function marker, is an insensitive indicator of early kidney injury because measurable elevation typically requires loss of a substantial fraction of functional nephron mass. This diagnostic lag has driven interest in biomarkers that reflect tubular cell injury or glomerular filtration changes earlier in the disease process, two of the most studied being neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C.
NGAL is expressed by renal tubular epithelial cells in response to ischemic or toxic injury and can be measured in both urine and plasma. Urinary NGAL reflects local tubular stress and is largely independent of glomerular filtration rate, making it a useful complement to filtration-based markers rather than a replacement for them. Because NGAL concentrations can also rise with systemic inflammation or urinary tract infection, interpretation in companion animal research should account for concurrent inflammatory status rather than treating NGAL as a renal-specific signal in isolation.
Cystatin C is a low-molecular-weight protein produced at a relatively constant rate by nucleated cells and freely filtered at the glomerulus, with minimal tubular secretion. Its serum concentration is therefore more directly tied to glomerular filtration rate than creatinine, and unlike creatinine it is less influenced by muscle mass, which is a meaningful advantage in geriatric or cachectic companion animals where muscle mass is reduced independent of renal status.
| Biomarker | Biological source | Typical specimen | Interpretive note |
|---|---|---|---|
| NGAL | Renal tubular epithelium (injury-induced expression) | Urine (local), plasma/serum (systemic) | Rises with tubular stress; can be elevated by concurrent inflammation or infection |
| Cystatin C | Constitutively produced, freely filtered at glomerulus | Serum, plasma | Less affected by muscle mass than creatinine; reflects filtration status |
| Creatinine (reference) | Muscle metabolism byproduct | Serum, plasma | Insensitive to early injury; included for comparative study design only |
For studies designed around early renal change detection in cats and dogs, the kidney injury marker category groups NGAL, cystatin C and related assays together, and a deeper methodological comparison of these markers is available in a dedicated article on kidney injury biomarkers in veterinary research.
Immunoglobulin Class Kits Across Species: IgG, IgA, IgM, IgE
Immunoglobulin quantification supports a distinct set of research questions from inflammation or renal panels: humoral immune competence, passive transfer adequacy, mucosal immunity and allergic sensitization. Each immunoglobulin class has a characteristic biological role that determines which companion animal research contexts call for it.
IgG is the dominant serum immunoglobulin in both cats and dogs and is the primary readout for systemic humoral immune status, including studies of immunodeficiency, chronic infection response and, in neonatal research, passive transfer of maternal immunity via colostrum. IgA is concentrated at mucosal surfaces and in secretions, making it relevant to gastrointestinal and respiratory mucosal immunity research. IgM is the first antibody class produced in a primary immune response and is used as a marker of recent or acute antigen exposure before the IgG response matures. IgE, present at much lower serum concentrations than the other classes, is the principal mediator of immediate hypersensitivity and is used in allergic and parasitic research contexts in both species.
| Immunoglobulin | Primary biological role | Typical research use in cats/dogs | Relative serum concentration |
|---|---|---|---|
| IgG | Dominant systemic antibody, secondary immune response | Immune competence, passive transfer, chronic exposure studies | Highest |
| IgA | Mucosal and secretory immunity | GI and respiratory mucosal immune research | Moderate |
| IgM | Primary/acute immune response | Recent exposure or early infection marker | Moderate |
| IgE | Immediate hypersensitivity mediator | Allergy and parasitic sensitization research | Lowest |
Because antibody pair cross-reactivity between cat and dog immunoglobulins is not assured even within the same class, species-specific kits should be confirmed individually. The IgA/IgM/IgE panel category and the broader immunoglobulin and antibody kit category are organized to support this class-by-class comparison, and a more detailed breakdown of subclass considerations appears in the companion article on immunoglobulin subclass ELISA kits.
General Sandwich ELISA Methodology and Assay Workflow Principles
Nearly all of the biomarker kits discussed above rely on sandwich ELISA chemistry, in which the analyte of interest is captured between two antibodies recognizing distinct, non-overlapping epitopes. Understanding this shared workflow helps explain why sample quality, incubation conditions and species-specific antibody validation matter equally across CRP, NGAL, cystatin C and immunoglobulin assays.
- 1Plate coating
A capture antibody specific to the target analyte is immobilized on the microplate surface, typically during kit manufacture rather than by the end user.
- 2Sample and standard addition
Diluted samples and a dilution series of known-concentration standards are added to wells, allowing the analyte to bind the immobilized capture antibody.
- 3Washing
Unbound material is removed by repeated buffer washes, a step where incomplete technique is a common source of elevated background signal.
- 4Detection antibody binding
A second, enzyme-conjugated antibody binds a distinct epitope on the already-captured analyte, forming the \"sandwich\" that gives the method its name.
- 5Substrate development
Addition of an enzyme substrate produces a colorimetric signal proportional to the amount of bound detection antibody, and therefore to analyte concentration.
- 6Stop and read
A stop solution halts the enzymatic reaction at a defined endpoint, and absorbance is read on a microplate reader to generate raw optical density values.
- 7Curve fitting and quantification
Standard concentrations are plotted against their optical density values to build a standard curve, against which unknown sample concentrations are interpolated.
Because every step depends on antibody pairs matched to the target species, the species specificity issue raised earlier in kit selection is not a minor labeling detail; it is the mechanistic reason that a human or canine kit cannot be assumed to perform reliably on feline samples. A full treatment of plate layout, replicate strategy and quality control acceptance criteria is covered in the ELISA methodology applications resource, and in the dedicated article on sandwich ELISA methodology principles.
Building a Companion Animal Diagnostic Panel for Cats and Dogs
Individual biomarkers answer narrow questions; a panel answers a broader physiological one. A companion animal research design investigating systemic illness, for example, benefits from combining an inflammation marker (species-appropriate CRP or AGP), a renal marker (NGAL or cystatin C), and, where humoral status is relevant to the study, an immunoglobulin class assay. Running these in parallel on the same sample set allows a research team to distinguish inflammatory, renal and immune contributions to an observed phenotype rather than relying on a single data point.
| Research question | Recommended marker class | Species-specific note |
|---|---|---|
| Is there an active inflammatory process? | CRP (dog), AGP (cat) | Default marker differs by species; do not apply the same primary marker to both |
| Is there early tubular or filtration-related renal change? | NGAL (tubular), cystatin C (filtration) | Use together when distinguishing tubular injury from filtration decline |
| Is systemic humoral immunity adequate? | IgG | Primary marker in both species for passive transfer and chronic exposure studies |
| Is there evidence of recent antigen exposure? | IgM | Most informative early in an immune response timeline |
| Is mucosal or allergic immunity relevant? | IgA (mucosal), IgE (allergic) | Lower baseline concentrations require attention to assay sensitivity |
Panel design should also account for sample volume limits in cats, where repeated venipuncture is more constrained than in dogs; prioritizing assays with lower minimum sample volume requirements, or banking plasma and serum aliquots specifically for a planned panel, avoids re-collection partway through a study. Teams planning a combined inflammation, renal and immunoglobulin panel can review available species-specific options together in the companion animal diagnostics category before finalizing a study protocol, and should consult the applications resource for cross-cutting guidance on plate layout and replicate design that applies across all markers in the panel.